Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Issue 1 (28th October 2016)

• Record Type: Journal Article
• Authors: Petta, S.; Cabibbo, G.; Barbara, M.; Attardo, S.; Bucci, L.; Farinati, F.; Giannini, E. G.; Tovoli, F.; Ciccarese, F.; Rapaccini, G. L.; Di Marco, M.; Caturelli, E.; Zoli, M.; Borzio, F.; Sacco, R.; Virdone, R.; Marra, F.; Felder, M.; Morisco, F.; Benvegnù, L.; Gasbarrini, A.; Svegliati‐Baroni, G.; Foschi, F. G.; Olivani, A.; Masotto, A.; Nardone, G.; Colecchia, A.; Persico, M.; Boccaccio, V.; Craxì, A.; Bruno, S.; Trevisani, F.; Cammà, C.;
• Other Names: Biselli Maurizio investigator.; Caraceni Paolo investigator.; Cucchetti Alessandro investigator.; Domenicali Marco investigator.; Piscaglia Fabio investigator.; Gramenzi Annagiulia investigator.; Granito Alessandro investigator.; Magalotti Donatella investigator.; Serra Carla investigator.; Negrini Giulia investigator.; Napoli L. investigator.; Napoli Lucia investigator.; Salvatore Veronica investigator.; Benevento Francesca investigator.; Gazzola Alessia investigator.; Murer Francesca investigator.; Pozzan Caterina investigator.; Vanin Veronica investigator.; Moscatelli Alessandro investigator.; Pellegatta Gaia investigator.; Picciotto Antonino investigator.; Savarino Vincenzo investigator.; Poggio Paolo Del investigator.; Olmi Stefano investigator.; de Matthaeis Nicoletta investigator.; Balsamo Claudia investigator.; Vavassori Elena investigator.; Roselli Paola investigator.; Dell'Isola Serena investigator.; Ialungo Anna Maria investigator.; Rastrelli Elena investigator.; Rini Francesca investigator.; Costantino Andrea investigator.; Affronti Andrea investigator.; Affronti Marco investigator.; Mascari Marta investigator.; Mega Andrea investigator.; Pompili Maurizio investigator.; Rinninella Emanuele investigator.; Mismas Valeria investigator.; Dall'Aglio Anna Chiara investigator.; Feletti Valentina investigator.; Lanzi Arianna investigator.; Cappa Federica Mirici investigator.; Neri Elga investigator.; Stefanini Giuseppe Francesco investigator.; Tamberi Stefano investigator.; Biasini Elisabetta investigator.; Missale Gabriele investigator.; Guarino Maria investigator.; Ortolani Alessio investigator.; Chiaramonte Maria investigator.; Marchetti Fabiana investigator.; Valerio Matteo investigator.; Aburas Sami investigator.; Inghilesi Andrea L. investigator.; Cappelli Alberta investigator.; Golfieri Rita investigator.; Mosconi Cristina investigator.; Renzulli Matteo investigator.; Coccoli Piero investigator.; Zamparelli Marco Sanduzzi investigator.;
• Is Part Of: Alimentary pharmacology & therapeutics. Volume 45:Issue 1(2017)
• Page Start: 160
• Page End: 168
• Publication Date: 2016-10-28
• Subjects: Digestive organs -- Diseases -- Treatment -- Periodicals; Digestive organs -- Effect of drugs on -- Periodicals; Gastrointestinal system -- Diseases -- Treatment -- Periodicals; Gastrointestinal system -- Effect of drugs on -- Periodicals; 615.73
• DOI: 10.1111/apt.13821
• Languages: English
• ISSNs: 0269-2813

Abstract

Summary: Background: In HCV‐infected cirrhotic patients with successfully treated early hepatocellular carcinoma (HCC), the time to HCC recurrence and the effects of sustained viral eradication (SVR) by interferon (IFN)‐based or IFN‐free regimens on HCC recurrence remain unclear. Aim: To perform an indirect comparison of time to recurrence (TTR) in patients with successfully treated early HCC and active HCV infection with those of patients with SVR by IFN‐based and by IFN‐free regimens. Methods: We evaluated 443 patients with HCV‐related cirrhosis and Barcelona Clinic Liver Cancer Stage A/0 HCC who had a complete radiological response after curative resection or ablation. Active HCV infection was present in 328, selected from the Italian Liver Cancer group cohort; 58 patients had SVR achieved by IFN‐free regimens after HCC cure, and 57 patients had SVR achieved by IFN‐based regimens after HCC cure. Individual data of patients in the last two groups were extracted from available publications. Results: TTR by Kaplan–Meier curve was significantly lower in patients with active HCV infection compared with those with SVR both by IFN‐free ( P = 0.02) and by IFN‐based ( P < 0.001) treatments. TTR was similar in patients with SVR by IFN‐free or by IFN‐based ( P = 0.49) strategies. Conclusion: In HCV‐infected, successfully treated patients with early HCC, SVR obtained by IFN‐based or IFN‐free regimens significantly reduce tumour recurrence without differences related to the anti‐viral strategy used.